This retrospective analysis studied the impact of natural killer (NK) alloreactivity based on the missing ligand model, for a cohort of recipients undergoing haemopoietic stem cell transplant without T-cell depletion from HLA full-matched sibling donors. All patients received a uniform myeloablative conditioning regimen and prophylaxis for GVHD. A total of 151 patients were studied, including 62 patients with AML or myelodysplastic syndrome, 42 patients with ALL and 47 patients with CML. We found that 81% of patients had at least one missing KIR-ligand (KIR-L), and HLA-C1 allogroup homozygosity is present in 70% of patients. From multivariate analysis, we observed that the only consistently significant factor that was associated with superior survival was disease stage. Missing KIR-L, whether considering HLA-Bw and HLA-C alleles, without or with HLA-A ligands or narrowing to only HLA-C alleles alone to classify the number of missing KIR-L, did not have any impact on OS or relapse-free survival. This negative finding implies that as the KIR-L composition of recipient is not important in this matched non-T-depleted setting, further immunotherapeutic measures involving adoptive NK cell infusions have to be explored to exploit the benefit of NK alloreactivity for such transplants.
Introduction
Natural killer (NK) alloreactivity resulting in an improvement in haemopoietic stem cell transplant (HSCT) outcome was first reported in 2002 by the Perugia group for haploidentical transplants done for AML. 1 The advantage of NK alloreactivity is due to both NK-mediated lysis of susceptible AML blasts lacking the corresponding blocking HLA ligands thus reducing relapse, and the eradication of recipient's antigen presenting cells thereby preventing GVHD: a win-win situation that cannot be achieved by any T-cell mechanism. Since then there has been an abundance of literature exploring this factor in various transplant settings for various haematological malignancies. Although convincingly proven for haploidentical transplants, [1] [2] [3] [4] and with a similar pattern emerging for cord blood transplants, 5 the impact is not as consistent for other types of transplants.
The initial ligand-ligand model, also known as KIRligand (KIR-L) mismatch model, requires an incompatibility of the ligand of interest (most commonly based on HLA-Bw and C allogroups) between donor and recipient in the graft-vs-host direction, therefore confining the possibility of NK alloreactivity to only haploidentical 1,2,4 and HLA-mismatched transplants. [6] [7] [8] Subsequently, a second model known as receptor-ligand model (or missing ligand model) was proposed, where the consideration is on the KIR genotype rather than the KIR-L of the donor, and whether its corresponding ligand is missing in the recipient. 3, 9 As KIR genotype KIR2DL1, KIR2DL2/3, KIR3DL1 corresponding to HLA-C group 2, group 1 and HLA-Bw4 alleles are expressed frequently (100, 97 and 94%, respectively), 3, 9 the main factor becomes that of the recipient's HLA type, where homozygosity of HLA-C allogroups or absence of HLA Bw4 alleles signifies missing KIR-L and susceptibility to donor's NK recognition by their inhibitory killer-immunoglobulin-like receptor (iKIR). This model theoretically extends the possibility of NK alloreactivity to HLA full-matched HSCT, either unrelated or sibling, and even autologous transplants. 10, 11 There are several reports retrospectively analysing transplant outcome based on this model, with some showing advantage in certain aspects, for example OS, 9, 12 relapsefree survival (RFS), 9, 10, [12] [13] [14] [15] TRM, 11, 12, 16 whereas others failed to observe any beneficial effects. 11, 16 Heterogeneity of donor type, conditioning regimen, graft type, stem cell dose and manipulation are possible confounding factors and are problems inherent in some registry data.
Matched sibling transplant is the commonest allogeneic transplant in most centres as well as ours. As a single institution, our patient cohort is a homogeneous population receiving the same disease-specific conditioning protocol, GVHD prophylaxis regimen and un-manipulated HSCT. Here, we review our own HLA full-matched sibling transplant data to address the question of whether missing KIR-L in the recipient based on the missing ligand model confers any benefit.
Materials and methods

Study population
The diseases of interest for this review are AML, myelodysplastic syndrome (MDS), ALL and CML. Inclusion of patients into this retrospective analysis is based on the availability of archived DNA samples of the donorrecipient pairs, which was routinely obtained pre-transplant from mononuclear cell fractions and kept frozen at À80 1C.
Only patients with a diagnosis of AML, MDS, ALL or CML and who underwent an HLA full-matched sibling HSCT with a myeloablative regimen are included. The use of these samples and access to patient's clinical data are approved by the Institutional Review Board.
Molecular assays and classification
Donor's KIR genotyping was determined using PCR-SSP method (PEL-FREEZ KIR genotyping SSP kit, Dynal Biotech, WI, USA) as described by the manufacturer. Recipient's HLA typing was obtained from pre-existing records done at our HLA typing laboratory before transplant, which used the standard NIH microlymphocytotoxicity assay using commercially available sera for HLA A, B and C typing. In cases where there was only one HLA-C antigen detected by the above method, the HLA-C typing was performed by PCR-SSP using Micro SSP HLA C locus DNA typing tray (One-Lambda Inc., CA, USA) to detect the presence of a second allele (Cw12, Cw14, Cw15, Cw16, Cw17 and Cw18), which does not have any serological equivalent. In situations where the HLA-C allele type at low resolution was insufficient to allow classification into one of the two HLA-C allogroups (that is HLA-Cw3, Cw7, Cw12, Cw14, Cw15, Cw16), high-resolution typing was done using Micro SSP HLA C alleles-specific DNA typing tray (One-Lambda Inc). Allocation of alleles into exact HLA-C1/C2 and HLA-Bw4/Bw6 allogroups was based on published information. 17 Patients were therefore designated as missing ligand for KIR2DL1 (homozygous for HLA-C1 allogroup alleles), missing ligand for KIR2DL2/3 (homozygous for HLA-C2 allogroup alleles), or missing ligand for KIR3DL1 (homozygous for HLA-Bw6 and also not possessing HLA A23, A24 and A32, which were known ligands for KIR3DL1). 18 As a result, each patient was classified as having 0, 1 or 2 missing KIR-L and grouped as such. A subsequent rerun of the analysis took into consideration also missing ligand for KIR3DL2 (absence of HLA A3 and A11) and thus classifying patients into groups of missing either 0, 1, 2 or 3 KIR-L.
Clinical data
Clinical data were extracted from transplant registry case notes and online electronic clinical database. All patients with AML, MDS or CML received preparative regimen comprising of Busulphan (po 4 mg/kg/day or iv 3.2 mg/kg D-7 to D-4) and Cyclophosphamide (iv 60 mg/kg D-3 to D-2). All patients with ALL received Cyclophosphamide (iv 60 mg/kg D-5 to D-4) and TBI 1200 cGy (200 cGy twice daily D-3 to D-1). GVHD prophylaxis was standardized for all patients with iv CsA 3 mg/kg bd starting from D-3, titrating for trough level between 300 and 500 ug/l, and short course iv MTX. 19 No manipulation of BM or PBSCs was carried out and none of the patients received antithymocyte globulin.
For risk stratification, AML in first remission (CR1) and MDS, refractory anaemia (RA), ALL in CR1 and CML in first chronic phase (CP1) were classified as standard risk and all others as high risk. Gender risk was classified as high for sister-to-brother transplants and standard risk for all other combinations. CMV status of donor-recipient pairs classified patients into standard risk if both were CMV negative and high risk if either donor or recipients or both were positive by CMV total IgG. Graft type was classified into either BM or PBSC. Cell dose was dichotomized into two groups, that is above or below median dose for both BM and PBSC. OS duration is defined as period from HSCT date to date last seen or death. Relapse was defined as the earliest date of reappearance of leukaemic blasts in the peripheral blood subsequently confirmed on marrow study, or for CML, appearance of Philadelphia clone on cytogenetics study.
Statistical analysis
Statistical analysis was done using SPSS version 16.0 software. The datasets for AML/MDS, ALL and CML were separately analysed. Comparison of patients' baseline characteristics across the three groups of 0, 1 and 2 missing KIR-L was done using one-way ANOVA for continuous variables and two-sided Fisher's exact test for categorical variables. Analysis of survival outcome was done using Kaplan-Meier estimate for univariate analysis and log rank test for comparison between groups. Multivariate analysis was done using Cox proportion hazard model taking into account the following covariates: number of missing ligands (0, 1 or 2), disease stage (standard vs high risk), gender risk (standard vs high), CMV risk (standard vs high), graft type (BM vs PBSC), cell dose (below or above median), donor's age and patient's age (both continuous variables).
Results
A total of 151 patients with AML/MDS, ALL and CML who underwent full-matched sibling myeloablative transplant and had DNA available were included into this Missing KIR-ligand in non-T-depleted sibling transplant YC Linn et al Table 1 Baseline characteristics of all patients classified into three groups based on number of missing KIR-L This was higher than that reported by others. 9 Analysing further into these HLA types, a breakdown of the number of patients missing in each ligand is shown in Table 2 . It is interesting to note that homozygosity for HLA-C1 allogroup was present in 70% of patients and was much more frequent than HLA-C2 allogroup homozygosity. This may be a unique feature of Asian population, comparable to that reported for the Japanese marrow donors. 14 
KIR genotyping in donor cohort
We did KIR genotyping for the first cohort of 40 donors and observed that the KIR2DL1 and KIR2DL2/3 genotypes were present in all 40 donors, whereas KIR3DL1 was present in all except 1 of the 40 donors. This was consistent with that reported by others and we, therefore, classified patients based on their KIR-L alone, as has been done by other studies.
14,15
Effect on OS and RFS We analysed our survival data for these three diseases separately. The long-term OS of patients undergoing sibling HSCT for AML/MDS, ALL and CML were 67, 38 and 64%, respectively, for standard-risk disease and 17, 0 and 39%, respectively, for high-risk groups, as shown in Figure 1a and b. This is comparable to published outcome of myeloablative HSCT worldwide.
To study the effect of missing KIR-L in these patients, we first stratified patients by missing either 0, 1 or 2 KIR-L based on their HLA-Bw and C allogroups. For AML/ MDS, univariate analysis by Kaplan-Meier survival estimates and log rank comparison showed a significantly higher survival for those with two missing KIR-L compared with the groups with 1 missing KIR-L (pairwise P ¼ 0.018), with no difference between the groups with 0 and 1 missing KIR-L, see Figure 2 . However, multivariate analysis using Cox proportion hazard model showed disease stage and cell doses as the only two significant predictive factors of OS, whereas missing KIR-L did not reach any statistical significance, see Table 3 . There was also no difference in RFS between the three groups by multivariate analysis. When analysed only for standard-risk AML/MDS, that is AML in CR1 or MDS (RA), neither did missing KIR-L affect OS or RFS.
Similarly for ALL and CML, risk stratification into groups with 0, 1 or 2 missing KIR-L showed no impact on OS or RFS by either univariate or multivariate analysis. Not surprisingly, disease stage remained the only significant factor for both OS and RFS for both ALL and CML, with graft type (PBSC superior over BM) also significant for OS for CML, and female-to-male gender mismatch superior over other combinations for RFS for CML, see Table 3 .
As the number of patients in each disease group was small and might be inadequate to show statistical significance, we analysed all 151 patients as one group for any impact of missing ligand, and again found none, see Table 4 .
After observing absence of impact of missing HLA-Bw and C KIR-L, we went on to consider the additional ligands HLA-A3 and A11, which block KIR3DL2, thereby stratifying patients into groups with 0, 1, 2 or 3 missing KIR-L. The findings with this broadening of inclusion did not differ from that which considered only missing HLABw and HLA-C ligands. Finally, we narrowed down the analysis to consider only HLA-C, that is comparing between the two groups with HLA-C allogroups homozygosity vs heterozygosity, and similarly did not find any correlation with survival outcome.
Discussion
NK alloreactivity post-HSCT depends on multiple factors, including disease type, disease stage, HLA matching, presence of T cells and possibly immunosuppressants used for GVH prophylaxis or treatment. In this retrospective review, we aimed to analyse patients with AML/MDS, ALL and CML undergoing a uniform type of transplant, that is unmanipulated graft from HLA fullmatched sibling donors conditioned with a standardized myeloablative preparative regimen and uniform GVHD prophylaxis. This is also possibly the first such analysis for an Asian patient population. We hope to provide further data to the existing literature on the impact of missing KIR-L for this type of most commonly performed transplant.
In this analysis, we made the assumption that the majority of donors possess all three KIRs, which is supported by the findings of our 40 cases with KIR genotyping done and also based on that done by others. 14, 15 However, we do realize that this simplification may have overestimated the number of missing ligands. Although KIR3DL1 was present in 39 of the 40 donors genotyped, without allele typing of the KIR3DL1 gene complex, the number of donors with the non-expressed KIR3DL1*004 alleles is unknown. Therefore, an unknown proportion within the 64 patients with HLA-Bw6 homozygosity may be erroneously classified as having one missing HLA-B ligand contributing towards NK alloreactivity when in fact the KIR3DL1 allele did not recognize any missing ligand. We found that whether missing KIR-L does not affect transplant outcome in terms of OS and RFS. One important reason may be the presence of T cells in the graft. It is established that the presence of T cells 20, 21 and immunosuppressants 22 both affect NK reconstitution post-HSCT and this may then negate the beneficial effect of NK alloreactivity. We reviewed the literature for those HSCT from either matched siblings or matched unrelated donors, which were based on the missing ligand model. One series that involved in vitro T-cell depletion of the graft showed a convincing benefit of missing KIR-L, with a dose-effect proportional to the number of missing KIR-L. 9 Another unrelated donor registry series that included some cases with T-cell depletion showed a reduction in relapse rate for early myeloid leukaemia. 9, 15 On the other hand, other reports failed to show any benefit of missing KIR-L on outcome for matched sibling 16 and matched unrelated transplants.
14 There were two reports comprising of patient cohort most similar to ours, that is, HLA full matched, non-T-depleted sibling transplants, showing benefit of missing KIR-L. Sobecks et al. 12 reported 60 patients with AML where homozygosity of HLA-C is associated with superior OS, RFS and platelet engraftment. Of special interest is a small series reported by Clausen et al. 13 that included both myeloablative and reduced intensity transplants for AML/MDS, which additionally analysed the NK content of the graft. This study showed that a higher NK dose together with missing ligands reduce relapse rate significantly. These conflicting results even amongst apparently comparable study groups bring further questions. One conjecture will be other significant factors that were not being compared, for example intensity of GVHD prophylaxis and rapidity of its withdrawal, type and composition of graft where NK and T-cell dose differed significantly between PBSC and BM.
Our analysis showed that disease stage overrode other factors as the only consistent significant predictor of RFS and OS, which is not a surprising finding. Missing KIR-L was found not to be an important factor in this transplant setting. Although this observation may seem disappointing with the current understanding of benefit of NK alloreactivity in HSCT, it does not totally negate the prospect of harnessing NK alloreactivity in such a transplant setting. There is basis to be hopeful that missing KIR-L may still be exploited, especially in our patient population where a higher percentage of patients have at least one missing KIR-L. It is convincingly shown that unlicensed donor NK cells on infusion into an HLA-matched patient in an immediate post-HSCT milieu bypass the need for licensing and are alloreactive for the first few months. 23 It is also known that in vitro cytokine-activated NK cells are able to overcome the inhibition of cognate ligands and kill targets. 3 The lack of observed benefit from NK alloreactivity in a non-T-depleted, full-matched HSCT could therefore be potentially overcome by early infusion of large number of such activated donor NK cells, exploiting both the potency of cytokine-activated NK cells and the conducive milieu early post-HSCT. Various methods for large scale GMPcompliant expansion of NK cells have recently been described and are able to yield large number of NK cells. 24, 25 This could be adapted with further steps of NK purification to remove T cells, which may cause GVHD. It is worthwhile to prospectively explore NK 'add-back' early post-HSCT especially for high-risk diseases to preemptively reduce relapse rate. 
